دورية أكاديمية
SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
| العنوان: | SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. |
|---|---|
| المؤلفون: | Kundu K; Department of Thoracic/Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Cardnell RJ; Department of Thoracic/Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Zhang B; Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX, USA., Shen L; Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX, USA., Stewart CA; Department of Thoracic/Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Ramkumar K; Department of Thoracic/Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Cargill KR; Department of Thoracic/Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Wang J; Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX, USA., Gay CM; Department of Thoracic/Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA., Byers LA; Department of Thoracic/Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. |
| المصدر: | Translational lung cancer research [Transl Lung Cancer Res] 2021 Nov; Vol. 10 (11), pp. 4095-4105. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Hong Kong] : Pioneer Bioscience Publishing Company, [2012]- |
| مستخلص: | Background: Lurbinectedin recently received FDA accelerated approval as a second line treatment option for metastatic small cell lung cancer (SCLC). However, there are currently no established biomarkers to predict SCLC sensitivity or resistance to lurbinectedin or preclinical studies to guide rational combinations. Methods: Drug sensitivity was assayed in proliferation assays and xenograft models. Baseline proteomic profiling was performed by reverse-phase protein array. Lurbinectedin-induced changes in intracellular signaling pathways were assayed by Western blot. Results: Among 21 human SCLC cell lines, cytotoxicity was observed following lurbinectedin treatment at a low dose (median IC50 0.46 nM, range, 0.06-1.83 nM). Notably, cell lines with high expression of Schlafen-11 (SLFN11) protein, a promising biomarker of response to other DNA damaging agents (e.g., chemotherapy, PARP inhibitors), were more sensitive to single-agent lurbinectedin (FC =3.2, P=0.005). SLFN11 was validated as a biomarker of sensitivity to lurbinectedin using siRNA knockdown and in xenografts representing SLFN11 high and low SCLC. Replication stress and DNA damage markers (e.g., γH2AX, phosphorylated CHK1, phosphorylated RPA32) increased in SCLC cell lines following treatment with lurbinectedin. Lurbinectedin also induced PD-L1 expression via cGAS-STING pathway activation. Finally, the combination of lurbinectedin with the ataxia telangiectasia and Rad3-related protein (ATR) inhibitors ceralasertib and berzosertib showed a greater than additive effect in SLFN11-low models. Conclusions: Together our data confirm the activity of lurbinectedin across a large cohort of SCLC models and identify SLFN11 as a top candidate biomarker for lurbinectedin sensitivity. In SLFN11-low SCLC cell lines which are relatively resistance to lurbinectedin, the addition of an ATR inhibitor to lurbinectedin re-sensitized otherwise resistant cells, confirming previous observations that SLFN11 is a master regulator of DNA damage response independent of ATR, and the absence of SLFN11 leads to synthetic lethality with ATR inhibition. This study provides a rationale for lurbinectedin in combination with ATR inhibitors to overcome resistance in SCLC with low SLFN11 expression. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tlcr-21-437). Dr. CMG serves on advisory committees for Jazz Pharmaceuticals and AstraZeneca. Dr. LAB serves on advisory committees for Jazz Pharmaceuticals, AstraZeneca, Pharma Mar SA, and Merck and has research support from AstraZeneca. The other authors have no conflicts of interest to declare. (2021 Translational Lung Cancer Research. All rights reserved.) |
| References: | Bioinformatics. 2015 May 15;31(10):1692-4. (PMID: 25600946) Br J Cancer. 2021 Nov;125(10):1333-1340. (PMID: 34294893) PLoS One. 2016 Apr 07;11(4):e0152584. (PMID: 27055253) Cancer Cell. 2021 Mar 8;39(3):346-360.e7. (PMID: 33482121) Oncotarget. 2016 Nov 22;7(47):76534-76550. (PMID: 27708213) Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):. (PMID: 33536335) Mol Cancer Res. 2019 Mar;17(3):773-782. (PMID: 30552231) Clin Cancer Res. 2013 Nov 15;19(22):6322-8. (PMID: 24077350) Mol Cancer Ther. 2016 Oct;15(10):2399-2412. (PMID: 27630271) J Thorac Oncol. 2019 Dec;14(12):2152-2163. (PMID: 31470128) Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15030-5. (PMID: 22927417) Virchows Arch. 2021 Mar;478(3):569-579. (PMID: 32474729) Lancet. 2019 Nov 23;394(10212):1929-1939. (PMID: 31590988) Clin Cancer Res. 2015 Mar 1;21(5):1139-50. (PMID: 25733708) Mol Cell. 2018 Feb 1;69(3):371-384.e6. (PMID: 29395061) N Engl J Med. 2018 Dec 6;379(23):2220-2229. (PMID: 30280641) Clin Cancer Res. 2012 Oct 1;18(19):5399-411. (PMID: 22896654) Br J Cancer. 2017 Aug 22;117(5):628-638. (PMID: 28683469) Mol Cancer Ther. 2011 Aug;10(8):1481-9. (PMID: 21622731) Oncotarget. 2016 Jan 19;7(3):3084-97. (PMID: 26625211) J Clin Oncol. 2018 Aug 10;36(23):2386-2394. (PMID: 29906251) Clin Cancer Res. 2017 Jan 15;23(2):523-535. (PMID: 27440269) Nat Rev Dis Primers. 2021 Jan 14;7(1):3. (PMID: 33446664) Cancer Discov. 2019 May;9(5):646-661. (PMID: 30777870) Cancer Inform. 2009 Aug 05;7:199-216. (PMID: 19718451) Lancet Oncol. 2020 May;21(5):645-654. (PMID: 32224306) Cancer Cell. 2017 Feb 13;31(2):286-299. (PMID: 28196596) Oncotarget. 2017 Apr 25;8(17):28575-28587. (PMID: 28212573) Clin Cancer Res. 2020 Aug 15;26(16):4206-4215. (PMID: 32444417) Pharmacol Ther. 2019 Sep;201:94-102. (PMID: 31128155) Clin Cancer Res. 2021 Jul 15;27(14):3884-3895. (PMID: 33947690) |
| معلومات مُعتمدة: | U01 CA213273 United States CA NCI NIH HHS; R50 CA243698 United States CA NCI NIH HHS; R01 CA207295 United States CA NCI NIH HHS; P50 CA070907 United States CA NCI NIH HHS; T32 CA009666 United States CA NCI NIH HHS; P30 CA016672 United States CA NCI NIH HHS; T32 CA009302 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: SLFN11; Small cell lung cancer (SCLC); ataxia telangiectasia and Rad3-related protein (ATR); lurbinectedin; replication stress |
| تواريخ الأحداث: | Date Created: 20220110 Latest Revision: 20220716 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8674596 |
| DOI: | 10.21037/tlcr-21-437 |
| PMID: | 35004241 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2218-6751 |
|---|---|
| DOI: | 10.21037/tlcr-21-437 |